Crispr Therapeutics Price Target Raised to $82 as Casgevy Hits $116M Sales
Needham raised its price target to $82 from $80 after Casgevy generated $116 million in 2025 sales, surpassing Vertex’s $100 million goal. Chardan Capital set a $76 target implying 43% upside following FDA approval of Casgevy and 147 patient initiations last year.
1. Price Target Revisions
Needham increased its price target on Crispr Therapeutics to $82 from $80, maintaining a Buy rating after evaluating its fourth-quarter results. Chardan Capital also set a $76 target, forecasting 43% upside from current levels.
2. Casgevy 2025 Performance
Casgevy generated $54 million in fourth-quarter 2025 revenue and $116 million for the full year, exceeding Vertex’s $100 million goal. The therapy saw 147 patient initiations last year, nearly triple the prior year’s total.
3. FDA Approval and Collaboration Impact
FDA approval of Casgevy for sickle cell disease underscores the company’s gene-editing leadership and supports its collaboration with Vertex Pharmaceuticals. This partnership and regulatory milestone have driven investor optimism.
4. Stock Trading Reaction
Shares closed at $53.07 on February 13, reflecting an 8.46% gain and trading between $49.62 and $54.10. The stock’s market capitalization stands around $5.09 billion with volume at 2.46 million shares.